DNA-Based Blood Test Detects Down Syndrome as Early as the Tenth Week of Pregnancy
By LabMedica International staff writers Posted on 27 Oct 2014 |
Image: In contrast to tests that use MPSS (massively parallel shotgun sequencing), randomly sequencing all cell-free DNA (cfDNA), the Harmony test focuses on cfDNA from the chromosomes of interest. This unique, directed approach allows deeper analysis and ultimately yields more accurate results (Photo courtesy of Ariosa Diagnostics).
Down syndrome (Trisomy 21) can now be detected using a noninvasive blood test to evaluate cell-free DNA (cfDNA) found in maternal blood as early as 10 weeks into pregnancy.
The Ariosa Diagnostics (San Jose, CA, USA) Harmony Non-Invasive Prenatal Test (NIPT) exploits single nucleotide polymorphism (SNP) analysis to precisely quantify cfDNA and determine the fetal DNA contribution in a sample of the mother's blood. Risk assessment for Down syndrome based on fetal DNA measurement is assigned using FORTE, a proprietary algorithm.
Harmony is cited as being an accurate and reliable test that specifically targets the DNA in chromosomes 21, 18 and 13. While rare, these are the most common trisomies that occur in babies born to women of any age, when no other risk factors are known. While traditional blood tests can miss as many as 15% of Down syndrome cases in pregnant women, Harmony’s DNA-based technology claims to accurately identify more than 99% of cases.
The Harmony test incorporates extensive quality controls. These controls include precise measurement of the amount of the developing baby’s DNA in each sample, to ensure that there is enough DNA present to return a reliable result.
Recently Ariosa announced signing a multi-year supply agreement with Affymetrix (Santa Clara, CA, USA) that will integrate microarrays and instruments produced by Affymetrix into the Ariosa Harmony test framework.
“We are pleased with the Affymetrix partnership as they have been a solid and reliable supplier. Our work on the microarray opens up the possibility to further broaden access to the Harmony test via a kit decentralization strategy,” said Ken Song, CEO of Ariosa. “We are excited about the opportunity to improve prenatal care for women globally.”
“Our array and assay technologies are foundational genomic tools in reproductive health and oncology applications,” said Frank Witney, president and CEO of Affymetrix. “Our partners are providing innovative solutions for unmet needs in these critical areas. We are pleased to work with Ariosa to supply arrays and instrumentation in support of their global business strategy.”
A study published in the June 2014 issue of the journal Fetal Diagnosis and Therapy demonstrated better performance of the Harmony test incorporating Affymetrix microarrays in comparison to a next generation sequencing approach in regard to shorter turn-around time and improved precision in measuring chromosome concentration and fetal fraction of cell-free DNA.
Related Links:
Ariosa Diagnostics
Affymetrix
The Ariosa Diagnostics (San Jose, CA, USA) Harmony Non-Invasive Prenatal Test (NIPT) exploits single nucleotide polymorphism (SNP) analysis to precisely quantify cfDNA and determine the fetal DNA contribution in a sample of the mother's blood. Risk assessment for Down syndrome based on fetal DNA measurement is assigned using FORTE, a proprietary algorithm.
Harmony is cited as being an accurate and reliable test that specifically targets the DNA in chromosomes 21, 18 and 13. While rare, these are the most common trisomies that occur in babies born to women of any age, when no other risk factors are known. While traditional blood tests can miss as many as 15% of Down syndrome cases in pregnant women, Harmony’s DNA-based technology claims to accurately identify more than 99% of cases.
The Harmony test incorporates extensive quality controls. These controls include precise measurement of the amount of the developing baby’s DNA in each sample, to ensure that there is enough DNA present to return a reliable result.
Recently Ariosa announced signing a multi-year supply agreement with Affymetrix (Santa Clara, CA, USA) that will integrate microarrays and instruments produced by Affymetrix into the Ariosa Harmony test framework.
“We are pleased with the Affymetrix partnership as they have been a solid and reliable supplier. Our work on the microarray opens up the possibility to further broaden access to the Harmony test via a kit decentralization strategy,” said Ken Song, CEO of Ariosa. “We are excited about the opportunity to improve prenatal care for women globally.”
“Our array and assay technologies are foundational genomic tools in reproductive health and oncology applications,” said Frank Witney, president and CEO of Affymetrix. “Our partners are providing innovative solutions for unmet needs in these critical areas. We are pleased to work with Ariosa to supply arrays and instrumentation in support of their global business strategy.”
A study published in the June 2014 issue of the journal Fetal Diagnosis and Therapy demonstrated better performance of the Harmony test incorporating Affymetrix microarrays in comparison to a next generation sequencing approach in regard to shorter turn-around time and improved precision in measuring chromosome concentration and fetal fraction of cell-free DNA.
Related Links:
Ariosa Diagnostics
Affymetrix
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans